Journal of the American Academy of Dermatology · 2006
Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
El Tal Abdul Kader, Posner Marshall R, Spigelman Zachary, Ahmed A Razzaque
Аннотация
BACKGROUND: Rituximab is an anti-CD20 chimeric antibody that selectively targets B lymphocytes. Recently, it has been reported to be beneficial in treating pemphigus vulgaris.
OBJECTIVE: Our aim was to review the English-language literature on the treatment of pemphigus vulgaris (PV) with rituximab and to determine its efficacy and influence on clinical outcome(s).
MATERIAL AND METHODS: A retrospective review of the literature on the use of rituximab in the treatment of PV was conducted. Seventeen patients in 10 reports were described and their data were reviewed.
RESULTS: The majority of patients received one course of rituximab along with conventional immunosuppressive therapy as concomitant therapy; 88% of the patients demonstrated improvement. More than half of the patients were followed up for more than 6 months after rituximab treatment; they appeared to be clinically disease free, but were still receiving conventional immunosuppressive therapy. Side effects in most patients were transient and infusion related. Serious infections occurred in 4 patients. One patient died.
LIMITATIONS: The sample size of this study is small; there is no uniformity of data collection or measurement of key and critical indices, and follow-up was limited.
CONCLUSION: Rituximab may be a promising agent in treatment of PV.
OBJECTIVE: Our aim was to review the English-language literature on the treatment of pemphigus vulgaris (PV) with rituximab and to determine its efficacy and influence on clinical outcome(s).
MATERIAL AND METHODS: A retrospective review of the literature on the use of rituximab in the treatment of PV was conducted. Seventeen patients in 10 reports were described and their data were reviewed.
RESULTS: The majority of patients received one course of rituximab along with conventional immunosuppressive therapy as concomitant therapy; 88% of the patients demonstrated improvement. More than half of the patients were followed up for more than 6 months after rituximab treatment; they appeared to be clinically disease free, but were still receiving conventional immunosuppressive therapy. Side effects in most patients were transient and infusion related. Serious infections occurred in 4 patients. One patient died.
LIMITATIONS: The sample size of this study is small; there is no uniformity of data collection or measurement of key and critical indices, and follow-up was limited.
CONCLUSION: Rituximab may be a promising agent in treatment of PV.